Related Experiment Video

Updated: May 3, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

13.1K

[Rosiglitazone inhibits human HepG2 cell proliferation via PI3K/PTEN/Akt signaling pathway]

Meng Zhang1, Li Peng, Zhibin Qiao

  • 1Department of Hepatobiliary Surgery, Fourth Affiliated Hospital, Hebei Medical University, Shijiazhuang 050011, China.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi = Chinese Journal of Cellular and Molecular Immunology
|February 5, 2014
PubMed
Abstract

Insights

Rosiglitazone (ROZ) inhibits hepatocellular carcinoma HepG2 cell proliferation and blocks the cell cycle. These effects are linked to the PI3K/PTEN/Akt pathway, impacting Skp2 and P27(kip1) protein expression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Hepatocellular carcinoma (HCC) is a significant global health concern.
  • Understanding the molecular mechanisms underlying HCC proliferation is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the effects of rosiglitazone (ROZ) on HepG2 cell proliferation and cell cycle.
  • To explore the underlying molecular mechanisms involving key proteins and signaling pathways.

Main Methods:

  • HepG2 cells were treated with varying concentrations of ROZ.
  • Cell proliferation was assessed using MTT assay.
  • Cell cycle distribution was analyzed by flow cytometry.
  • Protein and mRNA expression levels of PTEN, pAkt, Skp2, and P27(kip1) were measured using Western blotting and RT-PCR.

Main Results:

  • ROZ significantly inhibited HepG2 cell proliferation in a dose- and time-dependent manner.
  • ROZ treatment led to an increased proportion of cells in the G0/G1 phase and a decrease in the S phase.
  • ROZ reduced pAkt and Skp2 expression while increasing PTEN and P27(kip1) expression at the protein level.
  • ROZ increased PTEN mRNA and decreased Skp2 mRNA levels, with no significant effect on P27(kip1) mRNA.

Conclusions:

  • ROZ effectively inhibits HepG2 cell proliferation and induces G0/G1 cell cycle arrest.
  • The observed effects are likely mediated through the PI3K/PTEN/Akt signaling pathway.
  • ROZ modulates the expression of Skp2 and P27(kip1), contributing to its anti-cancer effects in HCC.

More Related Videos

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

38.4K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
6.0K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K